Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Investigators return to Long Island home of Gilgo Beach serial killing suspect
Escaped zebra captured near Seattle after gallivanting around Cascade mountain foothills for days
Arsenal keeps up Premier League title push with 3
Kaia Gerber flashes a hint of her taut tummy in a T
Devout Christian doctor, 68, who punched dementia
Burnley slips closer to relegation from Premier League with 4
Why Pret's £4.50 cheddar baguette made me swear never to buy anything from the chain again
Adin Hill flashes old playoff form as Golden Knights beat Stars 2
Devout Christian doctor, 68, who punched dementia
Kate Hudson makes TV debut performing as singer on The Tonight Show Starring Jimmy Fallon